CoChat

Current therapy for chronic hepatitis C: The role of direct-acting antivirals

Open access
Li, Guangdi, De Clercq, Erik · 2017 · Antiviral Research
Cited by 174

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Abstract One of the most exciting developments in antiviral research has been the discovery of the direct‐acting antivirals (DAAs) that effectively cure chronic hepatitis C virus (HCV) infections. Based on more than 100 clinical trials and real‐world studies, we provide a comprehensive overview of FDA‐approved therapies and newly discovered anti‐HCV agents with a special focus on drug efficacy, mechanisms of action, and safety. We show that HCV drug development has advanced in multiple aspects: (i) interferon‐based regimens were replaced by interferon‐free regimens; (ii) genotype‐specific drugs evolved to drugs for all HCV genotypes; (iii) therapies based upon multiple pills per day were simplified to a single pill per day; (iv) drug potency increased from moderate (˜60%) to high (>90%) levels of sustained virologic responses; (v) treatment durations were shortened from 48 to 12 or 8 weeks; and (vi) therapies could be administered orally regardless of prior treatment history and cirrhotic status. However, despite these remarkable achievements made in HCV drug discovery, challenges remain in the management of difficult‐to‐treat patients. HighlightsHCV genotype‐specific drugs evolve to pan‐genotypic drugs.Drug potency increases from moderate (˜60%) to high (>90%) levels of sustained virologic response.Treatment durations are shortened from a 48‐week to 12‐week or 8‐week period.HCV therapies based upon multiple pills per day are simplified to a single pill per day.HCV therapies are administered orally regardless of prior treatment history and cirrhotic status.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.antiviral.2017.02.014

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 174

Metadata

Authors
Li, G., & De Clercq, E.
Venue
Antiviral Research
Publisher
Elsevier BV
Published
2017-06
Volume
142
Pages
83-122
ISSN
0166-3542 (ISSN-L)
OpenAlex
W2591108500
Cited by
174
References
6
FWCI
12.63
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.